Selatogrel
As of the edition of 20 October 2026, Selatogrel is a small molecule: in active development; acts on P2RY12.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 11, 0 stopped early
- Disease areas
- Cancer; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| P2RY12 | P2Y purinoceptor 12 | Q9H244 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 7 | 1 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Idorsia Pharmaceuticals | Lead sponsor of trials | 2011 to now |
| Viatris | Lead sponsor of trials | 2018 to now |